Showing 1661-1670 of 1732 results for "".
- Transdermal Donepezil Provides Drug Delivery Equivalent to Oral Donezepil With Favorable GI Side Effect Profilehttps://practicalneurology.com/news/transdermal-donepezil-provides-drug-delivery-equivalent-to-oral-therapy-with-favorable-gi-side-effect-profile/2469989/Results from a phase 1 trial (NCT04617782) show that both strengths of a donepezil transdermal system (Adlarity; Corium, Boston, MA) maintain equivalent daily exposure of donepezil compared to oral formulations of the drug and have a f
- Diazepam Nasal Spray for Acute Treatment of Seizure Clusters Easy to Use and Maintained Quality of Lifehttps://practicalneurology.com/news/diazepam-nasal-spray-for-acute-treatment-of-seizure-clusters-easy-to-use-and-maintained-quality-of-life/2469878/**This article was updated on April 13, 2022 to correct an error regarding the relative bioavailability of diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) compared with other formulations of diazepam. New data from the clinical development program for diazepam nasal spr
- Once-at-Bedtime Sodium Oxybate Therapy for Narcolepsy Preferred Among Patients and Clinicianshttps://practicalneurology.com/news/once-at-bedtime-sodium-oxybate-therapy-for-narcolepsy-preferred-among-patients-and-clinicians/2469855/Sodium oxybate therapy (FT218; Avadel Pharmaceuticals, Chesterfield, MO) with once-nightly dosing was preferred in a discrete choice experiment over twice-nightly dosing. Clinical trial results also show that this formulation of sodium oxybate improved daytime sleepiness, sleep quality, and refre
- Oral Solution of Celecoxib Becoming Available for Acute Migraine Treatmenthttps://practicalneurology.com/news/oral-solution-of-celecoxib-becoming-available-for-acute-migraine-treatment/2469757/Oral celecoxib (Elyxyb; BioDelivery Sciences International, Raleigh, NC and Dr. Reddy's Laboratories, Hyderabad, India) is a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. This formulation of celecoxib is currently not available in the US and
- First Patient Enrolled for Oral Edaravone Amyotrophic Lateral Sclerosis Treatmenthttps://practicalneurology.com/news/first-patient-enrolled-for-oral-edaravone-amyotrophic-lateral-sclerosis-treatment/2469741/The amyotrophic lateral sclerosis (ALS) Deceleration with ORal Edaravone (ADORE) phase 3 clinical trial for an oral formulation of edaravone (FNP122; Ferrer, Barcelona, Spain) has enrolled the first participant. The trial is being conducted in Europe and will enroll approximately 300 participants
- Extended-Release Carbidopa/Levodopa Improves Motor Fluctuations in Parkinson Diseasehttps://practicalneurology.com/news/extended-release-carbidopalevodopa-improves-motor-fluctuations-in-parkinson-disease/2469676/Data from a clinical trial (NCT03670953) show that a new formulation of extended-release carbidopa (CD)/levodopa (LD) (IPX-203; Amneal, Bridgewater, NJ) improved motor fluctuations of Parkinson disease (PD) compared with an immediate-r
- Expanding Detection and Increasing Community Education and Services for Alzheimer Diseasehttps://practicalneurology.com/news/expanding-detection-and-increasing-community-education-and-services-for-alzheimer-disease/2469599/A research collaboration (Hackensack Meridian Health and Eisai Inc.) to help address substantial unmet needs of individuals with Alzheimer disease (AD) has been initiated. This collaboration will focus specifically on mild cognitive impairment (MCI). "We are proud to join forces wi
- Sublingual Cannabidiol Tablet Shows Efficacy for Treating Diabetic Peripheral Neuropathy in Phase 2 Trialhttps://practicalneurology.com/news/sublingual-cannabidiol-tablet-shows-efficacy-for-treating-diabetic-peripheral-neuropathy-in-phase-2-trial/2469595/Treatment with a proprietary form of cannabidiol (CBD) as water-soluble sublingual tablets (Pure Green Pharmaceuticals, West Bloomfield, MI) provided statistically significant pain relief compared with placebo. In a confirmatory phase 2 clinical trial, (
- Immune Repopulation Study Suggests Cladribine Has No Negative Effect on Ability to Fight Injection or Benefit From Vaccinationhttps://practicalneurology.com/news/immune-repopulation-study-suggests-cladribine-has-no-negative-effect-on-ability-to-fight-injection-or-benefit-from-vaccination/2469580/New research suggests that cladribine (Mavenclad; Merck KGaA, Darmstadt, Germany) treatment for relapsing multiple sclerosis (RMS) does not diminish individuals' ability to fight infection or form antibodies after immunization. The MAGNIFY-MS sub-study (
- Evobrutinib Reduces Relapse Rate, Lesion Load, and Neurofilament Light Levelshttps://practicalneurology.com/news/evobrutinib-reduces-relapse-rate-lesion-load-and-neurofilament-light-levels/2469571/Post-hoc analysis of data from a trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MA) for relapsing forms of multiple sclerosis (MS) showed reduced levels of neurofilament light (NfL), a biomarker of axon degeneration. Partici